🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

René Bernards

The Netherlands Cancer Institute

ORCID: 0000-0001-8677-3423

Also affiliated with Shanghai Cancer Institute, Oncode Institute

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2023)10.1158/0008-5472.c.6497325
Top 100%
0DataRank
Top 100%0 citations

Ana M. González-Angulo, Aňa Lluch, Richard M. Neve, Wen-lin Kuo, Michael A. Davies +17 more

Papers

Driven by 13 papers — median percentile 0. Top paper: “Molecular basis of the anti-cancer effects of histone deacetylase inhibitors”.

Molecular basis of the anti-cancer effects of histone deacetylase inhibitors

The International Journal of Biochemistry & Cell Biology(2009)10.1016/j.biocel.2008.07.020
N/A
1.1DataRank · unranked
19 citations

René Bernards, Mirjam T. Epping

Protein phosphatase 2A regulatory subunits and cancer

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer(2009)10.1016/j.bbcan.2008.05.005
N/A
0.937DataRank · unranked
516 citations

Menno P. Creyghton, René Bernards, Pieter J.A. Eichhorn

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma

Cancer Letters(2019)10.1016/j.canlet.2019.07.004
N/A
0.612DataRank · unranked
58 citations

Anne van Wijngaarden, Arjan Kol, Gert J. Meersma, Mathilde Jalving, René Bernards +4 more

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors

Nature Cancer(2023)10.1038/s43018-022-00508-5
N/A
0.574DataRank · unranked
45 citations

Chloé E. Atreya, Changjun Wang, Bo Pan, Courtney A. Dreyer, Diede Brunen +20 more

Finding effective cancer therapies through loss of function genetic screens

Current Opinion in Genetics & Development(2014)10.1016/j.gde.2013.11.007
N/A
0.477DataRank · unranked
23 citations

René Bernards

Data from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation

(2023)10.1158/1078-0432.c.6527784.v1
N/A
0DataRank · unranked
0 citations

Jenny Y. Xue, Dennie T. Frederick, Yi Cao, Eva Lin, Catherine Wilson +8 more

Embracing cancer complexity: Hallmarks of systemic disease

Cell(2024)10.1016/j.cell.2024.02.009
N/A
0DataRank · unranked
481 citations

Elsa Bernard, Chris Abbosh, Fabrice Andre, Johan Auwerx, Allan Balmain +28 more

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

Nature reviews. Cancer(2024)10.1038/s41568-024-00737-z
N/A
0DataRank · unranked
156 citations

Mengnuo Chen, Elisa Mariella, Haoning Peng, Sumaiyah K. Rehman, Elena Sancho +17 more

Data from An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2023)10.1158/0008-5472.c.6497325
Top 100%
0DataRank
Top 100%0 citations

Ana M. González-Angulo, Aňa Lluch, Richard M. Neve, Wen-lin Kuo, Michael A. Davies +17 more

Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy

Angiogenesis(2022)10.1007/s10456-022-09863-4
N/A
0DataRank · unranked
53 citations

Judy R. van Beijnum, Christian J. Griffioen, Zowi R. Huinen, Nadine Grima Sopesens, Ralph Schulz +13 more

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF V600E colorectal tumors

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.10.20.512885
N/A
0DataRank · unranked
0 citations

Chloé E. Atreya, Changjun Wang, Bo Pan, Courtney A. Dreyer, Diede Brunen +20 more

Data from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2023)10.1158/0008-5472.c.6497889
N/A
0DataRank · unranked
0 citations

Magüi Gili, Maurizio Scaltriti, Violeta Serra, Marta Guzmán, Wouter Nijkamp +6 more

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial

ESMO Open(2025)10.1016/j.esmoop.2025.105892
N/A
0DataRank · unranked
0 citations

Salvatore Siena, A. Sartore-Bianchi, Javier Ros, F. Ciardello, E. Martinelli +38 more